CF PharmTech Inc
02652
Company Profile
Business description
CF PharmTech Inc is focused on the R&D, manufacturing and commercialization of inhalation technologies and inhalation drugs, with a focus on treating respiratory diseases. It has developed a product portfolio with a broad coverage of patients, medical specialties, and therapeutic areas. Its products strategically benchmark global blockbuster drugs, covering four of the top ten inhalation drugs. Its first-approved product CF017, a budesonide suspension for inhalation targeting bronchial asthma, marked its first approved product.
Contact
No. 16, Hucundang Road
Xiangcheng Economic Development District
Jiangsu
Suzhou
CHNT: +86 51286867555
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
605
Stocks News & Analysis
stocks
US utilities stocks keep rallying as investors bet on power demand growth
Rising electricity demand from data centers supports earnings growth, but Morningstar analysts say the sector looks less attractive after a sharp rally.
stocks
What did Morningstar subscribers buy and sell during March?
How the most traded shares in March stack up against our analysts views.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,165.10 | 41.30 | -0.45% |
| CAC 40 | 8,327.86 | 91.88 | 1.12% |
| DAX 40 | 24,044.22 | 301.78 | 1.27% |
| Dow JONES (US) | 48,535.99 | 317.74 | 0.66% |
| FTSE 100 | 10,609.06 | 26.10 | 0.25% |
| HKSE | 25,872.32 | 211.47 | 0.82% |
| NASDAQ | 23,639.08 | 455.35 | 1.96% |
| Nikkei 225 | 57,877.39 | 1,374.62 | 2.43% |
| NZX 50 Index | 13,038.47 | 21.21 | 0.16% |
| S&P 500 | 6,967.38 | 81.14 | 1.18% |
| S&P/ASX 200 | 8,970.80 | 43.20 | -0.48% |
| SSE Composite Index | 4,026.63 | 38.07 | 0.95% |